Literature DB >> 6217925

Erythrocyte adenosine deaminase, purine nucleoside phosphorylase and phosphoribosyltransferase activity in patients with Down's syndrome.

R Puukka, M Puukka, M Leppilampi, S L Linna, K Kouvalainen.   

Abstract

The erythrocyte adenosine deaminase, nucleoside phosphorylase, hypoxanthineguanine phosphoribosyltransferase and adenine phosphoribosyltransferase activities and plasma urate concentrations were measured in 20 cases of Down's syndrome and in 20 age- and sex-matched control subjects. The mean erythrocyte adenosine deaminase and adenine phosphoribosyltransferase activities and plasma urate concentrations were significantly higher in Down's syndrome subjects than in controls (p less than 0.001, p less than 0.01 and p less than 0.001, respectively). In all subjects studied there was a positive correlation between the erythrocyte adenosine deaminase activity and plasma urate concentration (r = 0.488, p less than 0.005). The concentrations of the erythrocyte adenine nucleotides, AMP, ADP and ATP, did not differ in Down's syndrome (n = 10) from those of control subjects (n = 10). The results suggest that the increase of plasma urate concentrations is a consequence of the increase in adenosine deaminase activity in Down's syndrome patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6217925     DOI: 10.1016/0009-8981(82)90301-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Evaluation of uric acid levels, thyroid function, and anthropometric parameters in Japanese children with Down syndrome.

Authors:  Tomomi Niegawa; Kimitaka Takitani; Ryuzo Takaya; Manabu Ishiro; Yuichi Kuroyanagi; Keisuke Okasora; Yukako Minami; Takuya Matsuda; Hiroshi Tamai
Journal:  J Clin Biochem Nutr       Date:  2017-08-18       Impact factor: 3.114

Review 2.  Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome.

Authors:  Laszlo Pecze; Elisa B Randi; Csaba Szabo
Journal:  Mol Med       Date:  2020-11-09       Impact factor: 6.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.